{
    "title": "103_hr2695",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Pharmaceutical Testing Fairness \nAct''.\n\nSEC. 2. NEW DRUG CLINICAL INVESTIGATIONS.\n\n    Section 505(b) of the Federal Food, Drug, and Cosmetic Act is \namended by adding at the end the following:\n    ``(4)(A) Clinical investigations submitted as part of an \napplication in accordance with paragraph (1)(A) shall include women and \nmembers of minority groups as subjects of such investigations unless \nthe inclusion of women and minority groups is inappropriate with \nrespect to the drug under investigation or is otherwise inappropriate \nunder such guidelines as the Secretary shall by rule establish in \naccordance with subparagraph (B).\n    ``(B) The guidelines of the Secretary respecting the inclusion of \nwomen and members of minority groups in clinical investigations--\n            ``(i) shall provide that the costs of such inclusion is not \n        a permissible consideration in determining whether such \n        inclusion is inappropriate,\n            ``(ii) shall provide that women or minority groups are not \n        required to be included if women or minority groups will not be \n        using the drug under investigation, and\n            ``(iii) may provide that such inclusion is not required if \n        there is substantial scientific data demonstrating that there \n        is no significant difference between the effects that the \n        variables to be studied in the investigation have on women or \n        members of minority groups, respectively, and on the other \n        individuals who would serve as subjects in the investigation in \n        the event that the inclusion of women and members of minority \n        groups was not required.\n    ``(C) Phase three clinical investigations which are submitted as \npart of an application in accordance with paragraph (1)(A) shall be \ndesigned so that there is a valid analysis of whether the drug under \ninvestigation affects women or members of minority groups differently \nthan other users of the drug. If the Secretary determines that it would \nbe appropriate for other phases of such investigations to be so \ndesigned, such other phases shall be so designed.''.\n\nSEC. 3. DEVICE CLINICAL INVESTIGATIONS.\n\n    Section 515(c) of the Federal Food, Drug, and Cosmetic Act (21 \nU.S.C. 360e(c)) is amended by adding at the end the following:\n    ``(3)(A) Clinical investigations submitted as part of an \napplication in accordance with paragraph (1) shall include women and \nmembers of minority groups as subjects of such investigations unless \nthe inclusion of women and minority groups is inappropriate with \nrespect to the device under investigation or is otherwise inappropriate \nunder such guidelines as the Secretary shall by rule establish in \naccordance with subparagraph (B).\n    ``(B) The guidelines of the Secretary respecting the inclusion of \nwomen and members of minority groups in clinical investigations--\n            ``(i) shall provide that the costs of such inclusion is not \n        a permissible consideration in determining whether such \n        inclusion is inappropriate,\n            ``(ii) shall provide that women or minority groups are not \n        required to be included if women or minority groups will not be \n        using the device under investigation, and\n            ``(iii) may provide that such inclusion is not required if \n        there is substantial scientific data demonstrating that there \n        is no significant difference between the effects that the \n        variables to be studied in the investigation have on women or \n        members of minority groups, respectively, and on the other \n        individuals who would serve as subjects in the investigation in \n        the event that the inclusion of women and members of minority \n        groups was not required.\n    ``(C)(i) Clinical investigations designated by the Secretary under \nclause (ii) which are submitted as part of an application in accordance \nwith paragraph (1) shall be designed so that there is a valid analysis \nof whether the device under investigation affects women or members of \nminority groups differently than other users of the device.\n    ``(ii) The Secretary shall designate which of the clinical \ninvestigations submitted as part of an application under paragraph (1) \nshall be subject to the requirement of clause (i).''.\n\nSEC. 5. BIOLOGICAL PRODUCTS CLINICAL INVESTIGATIONS.  \n\n    Section 351(c) of the Public Health Service Act (42 U.S.C. 262(c)) \nis amended by adding at the end the following:\n    ``(3)(A) Clinical investigations submitted as part of an \napplication in accordance with paragraph (1) shall include women and \nmembers of minority groups as subjects of such investigations unless \nthe inclusion of women and minority groups is inappropriate with \nrespect to the biological product under investigation or is otherwise \ninappropriate under such guidelines as the Secretary shall by rule \nestablish in accordance with subparagraph (B).\n    ``(B) The guidelines of the Secretary respecting the inclusion of \nwomen and members of minority groups in clinical investigations--\n            ``(i) shall provide that the costs of such inclusion is not \n        a permissible consideration in determining whether such \n        inclusion is inappropriate,\n            ``(ii) shall provide that women or minority groups are not \n        required to be included if women or minority groups will not be \n        using the biological product under investigation, and\n            ``(iii) may provide that such inclusion is not required if \n        there is substantial scientific data demonstrating that there \n        is no significant difference between the effects that the \n        variables to be studied in the investigation have on women or \n        members of minority groups, respectively, and on the other \n        individuals who would serve as subjects in the investigation in \n        the event that the inclusion of women and members of minority \n        groups was not required.\n    ``(C)(i) Clinical investigations designated by the Secretary under \nclause (ii) which are submitted as part of an application in accordance \nwith paragraph (1) shall be designed so that there is a valid analysis \nof whether the device under investigation affects women or members of \nminority groups differently than other users of the device.\n    ``(ii) The Secretary shall designate which of the clinical \ninvestigations submitted as part of an application under paragraph (1) \nshall be subject to the requirement of clause (i).''."
}